Analytical Immunopharmacology

分析免疫药理学

基本信息

批准号：
10696183
负责人：
TIMOTHY W SYNOLD
金额：
$ 8.23万
依托单位：
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-13 至 2026-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10696183
关键词：
Address Analytical Chemistry Bioinformatics Biological Assay Biological Markers Biological Products Biological Response Modifier Therapy Blood - brain barrier anatomy Brain Central Nervous System Central Nervous System Neoplasms Cerebrospinal Fluid City of Hope Comprehensive Cancer Center Clinical Clinical Trials Collaborations Complex Comprehensive Cancer Center Consultations Correlative Study Data Analyses Development Drug Delivery Systems Drug Kinetics Elements Enzyme-Linked Immunosorbent Assay Experimental Designs Future Glioblastoma Goals High Pressure Liquid Chromatography Human Resources Immunoassay Immunochemistry Immunologics Inductively Coupled Plasma Mass Spectrometry Intercellular Fluid Investigation Knowledge Ligands Liquid substance Microdialysis Molecular Profiling Patients Pharmaceutical Preparations Pharmacodynamics Pharmacology Study Plasma Protein Secretion Protocols documentation Qualifying Research Research Design Research Personnel Research Project Grants Sampling Serum Services Techniques Therapeutic Time Training Translational Research Work Writing analytical method chemokine clinical development cytokine design effective therapy experience immunopharmacology instrumentation interstitial method development novel novel therapeutic intervention novel therapeutics participant enrollment pharmacodynamic model pharmacokinetics and pharmacodynamics preclinical development programs response small molecule small molecule inhibitor therapeutic development tumor

项目摘要

PROJECT SUMMARY – CORE A The Analytical Immunopharmacology Core (Core A) is designed to meet the specific drug and biologic therapeutic development needs of each of the U19 Research Projects and at the same time draw on the strength of the existing City of Hope Comprehensive Cancer Center (COHCCC) cores without unnecessary duplication of services. Core A will work closely and synergistically with COHCCC cores, as well as with the U19 Administrative Core and the Molecular Profiling and Bioinformatics Core (Core B) to provide exceptional support for all of the proposed Research Projects and inter-U19 collaborations. The overarching goals of Core A are to assist the Glioblastoma Therapeutics Network (GTN) U19 Project Leaders with pharmacokinetic (PK) and pharmacodynamic (PD) correlative studies performed in support of the proposed clinical trials. The work will be accomplished by leveraging the Core’s significant expertise in intracerebral microdialysis (ICMD), analytical chemistry, and analytical immunochemistry, as well as its access to state-of-the-art instrumentation. The overall purpose will be achieved through the following Specific Aims: Aim 1. Provide conceptual and analytical support to U19 investigators for correlative neuro-PK analyses (e.g., analysis of drugs and metabolites in the CNS). Support provided by Core A to U19 investigators under this aim will include all aspects of ICMD neuro-PK studies, including experimental design, analytical method development, sample analysis, and final interpretation of the data. Core A is staffed by highly trained personnel and equipped with analytical instrumentation that will be ideal for the quantitative analyses of small molecules (e.g., LC-MS/MS and ICP-MS/MS). Aim 2. Provide conceptual and analytical support to U19 investigators for their correlative neuro-PD analyses (e.g., analysis of biomarkers of drug response in the CNS). Support provided by Core A to U19 investigators under this aim will include all aspects of ICMD neuro-PD studies, including experimental design, analytical method development, sample analysis, and final interpretation of the data. Core A will provide a spectrum of immunoassay platforms (e.g., Luminex and ELISA) in the context of ICMD neuro-PD studies in support of the proposed clinical trials.

项目摘要 – 核心 A 分析免疫药理学核心（核心 A）旨在满足特定药物和生物制品的需求每个U19研究项目的治疗发展需求，同时利用力量现有希望之城综合癌症中心 (COHCCC) 核心，避免不必要的重复核心 A 将与 COHCCC 核心以及 U19 密切协作。行政核心和分子分析和生物信息学核心（核心 B）提供特殊支持对于所有拟议的研究项目和 U19 之间的合作，核心 A 的总体目标是：协助胶质母细胞瘤治疗网络 (GTN) U19 项目负责人进行药代动力学 (PK) 和为了支持拟议的临床试验而进行的药效学（PD）相关研究将是。通过利用核心在脑内微透析（ICMD）、分析化学和分析免疫化学，以及使用最先进的仪器。目的将通过以下具体目标来实现：目标 1. 为 U19 研究人员进行相关神经 PK 分析提供概念和分析支持（例如，中枢神经系统中的药物和代谢物分析）由核心 A 向 U19 研究人员提供的支持。这一目标将包括 ICMD 神经药代动力学研究的各个方面，包括实验设计、分析方法数据的开发、样本分析和最终解释由训练有素的人员组成。并配备了适合小分子定量分析的分析仪器（例如，LC-MS/MS 和 ICP-MS/MS）。目标 2. 为 U19 研究人员的相关神经 PD 提供概念和分析支持分析（例如，核心 A 向 U19 提供的中枢神经系统药物反应生物标志物分析）。在此目标下，研究人员将涵盖 ICMD 神经 PD 研究的各个方面，包括实验设计、分析方法开发、样品分析和数据的最终解释将提供一个。 ICMD 神经 PD 研究背景下的一系列免疫分析平台（例如 Luminex 和 ELISA）支持拟议的临床试验。